Dendreon (DNDN -5.9%) continues to fall after its Q2 earnings miss and restructuring this week,...
Dendreon (DNDN -5.9%) continues to fall after its Q2 earnings miss and restructuring this week, with SA author Amy Baldwin saying the company is approaching the end of the road. However, Galena Biopharma (GALE -2.9%), which is developing a vaccine to prevent the recurrence of breast cancer, should thrive even though it fell steeply following Dendreon's results.
From other sites
at Zacks.com (Mar 18, 2015)
at Zacks.com (Mar 9, 2015)
at CNBC.com (May 21, 2014)
at CNBC.com (Apr 8, 2014)
at CNBC.com (Mar 17, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs